Springworks Drug Patent Portfolio

Springworks owns 1 orange book drug protected by 24 US patents Given below is the list of Springworks's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11872211 Treatments with nirogacestat 19 May, 2043
Active
US11925619 Treatments with nirogacestat 19 May, 2043
Active
US11925620 Treatments with nirogacestat 19 May, 2043
Active
US11938116 Treatments with nirogacestat 19 May, 2043
Active
US11951096 Treatments with nirogacestat 19 May, 2043
Active
US11957662 Treatments with nirogacestat 19 May, 2043
Active
US12011434 Treatments with nirogacestat 19 May, 2043
Active
US12011435 Treatments with nirogacestat 19 May, 2043
Active
US12036207 Treatments with nirogacestat 19 May, 2043
Active
US11807611 Chlorinated tetralin compounds and pharmaceutical compositions 08 Sep, 2042
Active
US11844780 Chlorinated tetralin compounds and pharmaceutical compositions 08 Sep, 2042
Active
US11504354 Chlorinated tetralin compounds and pharmaceutical compositions 08 Jul, 2042
Active
US11612588 Chlorinated tetralin compounds and pharmaceutical compositions 08 Jul, 2042
Active
US10590087 Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof 09 Aug, 2039
Active
US10710966 Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof 09 Aug, 2039
Active
US10941118 Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof 09 Aug, 2039
Active
US11820748 Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof 09 Aug, 2039
Active
US11845732 Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof 09 Aug, 2039
Active
US11884634 Compositions of solid forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4- tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide 09 Aug, 2039
Active
US11884635 Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof 09 Aug, 2039
Active
US11905255 Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof 09 Aug, 2039
Active
US7342118 Imidazole compounds for the treatment of neurodegenerative disorders 18 Aug, 2025
Active
US7795447 Imidazole compounds for the treatment of neurodegenerative disorders 18 Aug, 2025
Active
US7951958 Imidazole compounds for the treatment of neurodegenerative disorders 11 Mar, 2025
Active


Given below is the list of recent legal activities going on the following drug patents of Springworks.

Activity Date Patent Number
Patent litigations
Electronic Review 07 Jun, 2024 US11951096
Second letter to regulating agency to determine regulatory review period 26 Apr, 2024 US7951958
Second letter to regulating agency to determine regulatory review period 26 Apr, 2024 US7795447
Second letter to regulating agency to determine regulatory review period 26 Apr, 2024 US7342118
Letter from FDA or Dept of Agriculture re PTE application 17 Apr, 2024 US7951958
Letter from FDA or Dept of Agriculture re PTE application 17 Apr, 2024 US7342118
Email Notification 17 Apr, 2024 US11957662
Letter from FDA or Dept of Agriculture re PTE application 17 Apr, 2024 US7795447
Mail Patent eGrant Notification 16 Apr, 2024 US11957662
Recordation of Patent eGrant 16 Apr, 2024 US11957662
Recordation of Patent Grant Mailed 16 Apr, 2024 US11957662
Patent eGrant Notification 16 Apr, 2024 US11957662
Patent Issue Date Used in PTA Calculation 16 Apr, 2024 US11957662
Recordation of Patent eGrant 09 Apr, 2024 US11951096
Patent Issue Date Used in PTA Calculation 09 Apr, 2024 US11951096


Springworks's Family Patents


Family Patents



Springworks Drug List

Given below is the complete list of Springworks's drugs and the patents protecting them.


1. Ogsiveo

Ogsiveo is protected by 24 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11872211 Treatments with nirogacestat 19 May, 2043
(18 years from now)
Active
US11925619 Treatments with nirogacestat 19 May, 2043
(18 years from now)
Active
US11925620 Treatments with nirogacestat 19 May, 2043
(18 years from now)
Active
US11938116 Treatments with nirogacestat 19 May, 2043
(18 years from now)
Active
US11951096 Treatments with nirogacestat 19 May, 2043
(18 years from now)
Active
US11957662 Treatments with nirogacestat 19 May, 2043
(18 years from now)
Active
US12011434 Treatments with nirogacestat 19 May, 2043
(18 years from now)
Active
US12011435 Treatments with nirogacestat 19 May, 2043
(18 years from now)
Active
US12036207 Treatments with nirogacestat 19 May, 2043
(18 years from now)
Active
US11807611 Chlorinated tetralin compounds and pharmaceutical compositions 08 Sep, 2042
(17 years from now)
Active
US11844780 Chlorinated tetralin compounds and pharmaceutical compositions 08 Sep, 2042
(17 years from now)
Active
US11504354 Chlorinated tetralin compounds and pharmaceutical compositions 08 Jul, 2042
(17 years from now)
Active
US11612588 Chlorinated tetralin compounds and pharmaceutical compositions 08 Jul, 2042
(17 years from now)
Active
US10590087 Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof 09 Aug, 2039
(14 years from now)
Active
US10710966 Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof 09 Aug, 2039
(14 years from now)
Active
US10941118 Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof 09 Aug, 2039
(14 years from now)
Active
US11820748 Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof 09 Aug, 2039
(14 years from now)
Active
US11845732 Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof 09 Aug, 2039
(14 years from now)
Active
US11884634 Compositions of solid forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4- tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide 09 Aug, 2039
(14 years from now)
Active
US11884635 Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof 09 Aug, 2039
(14 years from now)
Active
US11905255 Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof 09 Aug, 2039
(14 years from now)
Active
US7342118 Imidazole compounds for the treatment of neurodegenerative disorders 18 Aug, 2025
(10 months from now)
Active
US7795447 Imidazole compounds for the treatment of neurodegenerative disorders 18 Aug, 2025
(10 months from now)
Active
US7951958 Imidazole compounds for the treatment of neurodegenerative disorders 11 Mar, 2025
(4 months from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Ogsiveo's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List